- In April 2025, Guardant Health presented data demonstrating the strong performance of its Shield Multi-Cancer Detection (MCD) test across 10 tumor types, including breast cancer. The test exhibits high specificity and clinically meaningful sensitivity, with results informing the National Cancer Institute's selection of the Shield MCD test for the highly anticipated Vanguard Study
- In February 2025, Philips showcased new AI-enabled systems, intelligent software, and imaging cloud services at the European Congress of Radiology (ECR) 2025. These innovations aim to streamline radiology workflows and advance clinical insights, enhancing the efficiency and accuracy of breast imaging procedures
- In February 2025, the UK's National Health Service (NHS) launched the world's most extensive trial of AI in breast cancer diagnosis, analyzing approximately 700,000 mammograms over several years. The trial seeks to evaluate AI's accuracy compared to radiologists, with the potential to reduce workload and expedite diagnoses
- In October 2024, Densitas announced a strategic collaboration with the Medical Technology Management Institute (MTMI) to integrate MTMI’s educational content into Densitas’ intelliMammo platform. This partnership aims to provide continuous quality improvement in mammography by offering technologists access to expert educational materials, including positioning videos, thereby enhancing clinical image quality and patient care
- In March 2024, Hologic introduced its Genius AI Detection technology. This deep-learning software assists radiologists in detecting subtle potential cancers in breast tomosynthesis images, improving diagnostic accuracy and workflow efficiency. The technology is designed to categorize and prioritize cases by complexity, aiding in expedited patient care
